ESA regulatory moves prompt narrowing of Hematide indications
This article was originally published in Scrip
Executive Summary
Takedaand partner Affymax have decided to halt the development of their anaemia therapy Hematide in the oncology setting, pointing to "uncertain regulatory landscapes". The development programme for the erythropoiesis-stimulating agent (ESA) will now focus solely on anaemia related to chronic kidney disease.